# BioAtla, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/BioAtla, Inc.).

## Overview

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing conditionally active biologic antibody therapies through its proprietary CAB technology platform. Its pipeline includes antibody-drug conjugates and T-cell engaging bispecific antibodies aimed at oncology targets such as AXL, ROR2, CTLA-4, EpCAM, and Nectin-4. The company does not have approved products or a commercial sales organization, so its business is centered on research, clinical development, and licensing collaborations. BioAtla has also used out-licensing to generate collaboration revenue and milestone potential while it continues to fund development of its own product candidates.

## Products & services

• CAB technology platform for conditionally active biologics
• Mecbotamab vedotin (BA3011), a CAB AXL-ADC
• Ozuriftamab vedotin (BA3021), a CAB ROR2-ADC
• Evalstotug (BA3071), a CAB CTLA-4 program
• BA3182, a CAB EpCAM x CAB CD3 bispecific
• BA3362, a Nectin-4 x CD3 bispecific licensed to Context
• Collaboration, licensing, and preclinical research services

- **Clinical-stage oncology drug candidates** (0%) — Experimental antibody-based cancer therapies in preclinical and Phase 1/2 development.
- **CAB antibody-drug conjugates** (0%) — Conditionally active ADC programs designed to target tumors while limiting activity in healthy tissue.
- **CAB bispecific antibodies** (0%) — T-cell engaging and other bispecific antibody programs built on the CAB platform.
- **Licensing and collaboration revenue** (100%) — Upfront, milestone, and potential royalty income from out-licensing selected programs.

- CAB technology platform for conditionally active biologics
- Mecbotamab vedotin (BA3011), a CAB AXL-ADC
- Ozuriftamab vedotin (BA3021), a CAB ROR2-ADC
- Evalstotug (BA3071), a CAB CTLA-4 program
- BA3182, a CAB EpCAM x CAB CD3 bispecific
- BA3362, a Nectin-4 x CD3 bispecific licensed to Context
- Collaboration, licensing, and preclinical research services

## Customers

BioAtla does not currently sell approved products to end customers, so its near-term counterparties are primarily pharmaceutical and biotechnology collaborators. The company’s disclosed revenue has come from licensing arrangements, such as the Context Therapeutics agreement for BA3362, which can generate upfront, milestone, and research-funding payments. If any product is approved in the future, the ultimate buyers would be hospitals, oncology specialists, and payors, but BioAtla currently lacks a commercial sales organization and would need partners or a new internal sales force. In the current stage of the business, value is created by partnering assets, advancing clinical data, and converting pipeline programs into licensing opportunities.

- **Licensing partners** (primary) — Biotechnology or pharmaceutical companies that acquire rights to programs such as BA3362 to develop and commercialize them, paying upfront, milestone, and royalty consideration.
- **Research collaborators** (secondary) — Third parties that fund or co-fund preclinical research and development work tied to specific programs or pre-IND activities.
- **Future oncology treatment providers** (emerging) — Hospitals, oncology clinics, and specialists that would prescribe approved therapies if BioAtla or a partner commercializes a product.
- **Future payors** (emerging) — Government and commercial insurers that would determine reimbursement and access for any approved oncology product.

- Biopharma partners that license pipeline assets for development and commercialization
- Collaborators that fund preclinical work or milestone-based development programs
- Potential future oncology prescribers if any candidate reaches approval
- Hospitals and cancer centers would be the end-market users in a commercial scenario
- Payers and reimbursement systems would matter for adoption after approval

## Geography

BioAtla is headquartered in the United States and currently conducts its business primarily through U.S.-based research, development, and corporate operations. The company has stated that it may commercialize product candidates in the United States and foreign jurisdictions, but it does not yet have a marketing or sales organization. Its operating model therefore has limited geographic revenue exposure today, with future exposure depending on where partners take licensed assets and where any approved products are launched. The company also faces cross-border regulatory, data privacy, and capital-market risks that can affect development and financing decisions.

- Headquartered in the United States
- R&D and corporate functions are centered in the U.S.
- No current commercial sales footprint
- Future commercialization could extend to foreign jurisdictions through partners
- Cross-border regulatory and privacy requirements may affect operations

## Strategy

BioAtla’s strategy is to advance its CAB platform into differentiated oncology assets and use clinical data to support partnering, licensing, and eventual commercialization. Near term, the company is focused on progressing its Phase 1 and Phase 2 programs while controlling spending and preserving capital. It has already shown a willingness to monetize selected assets through licensing, as seen in the Context Therapeutics transaction for BA3362. Longer term, BioAtla needs either successful partnering or substantial new financing to support late-stage development and any future commercial build-out.

- **Progress key CAB clinical programs** (short-term) — Clinical data is the main driver of value for a pre-commercial biotech and determines whether programs can be partnered or advanced.
- **Monetize selected assets through collaborations and licensing** (short-term) — Partnerships can provide funding, external validation, and a path to value realization without building a full commercial organization.
- **Secure additional capital and manage burn** (short-term) — The company disclosed substantial doubt about going concern and expects to need additional funding to continue operations.
- **Create a path to commercialization or partner-led launch** (medium-term) — Without a sales organization, BioAtla must either build commercial capabilities or rely on third parties to reach patients.

- Advance CAB oncology programs through early and mid-stage clinical trials
- Use out-licensing to fund development and create non-dilutive value
- Prioritize programs with the strongest clinical and partnering potential
- Preserve cash while the company remains pre-commercial
- Build optionality for future commercialization or partner-led launch

## Risks

BioAtla is exposed to the classic risks of a clinical-stage biotech: its product candidates may fail in development, clinical timelines may slip, and regulatory approval may never be achieved. The company has no approved products, no commercial sales organization, and a history of losses, so its ability to continue operations depends on raising capital and/or securing collaborations on acceptable terms. Because it relies heavily on its CAB platform, any scientific or safety setback could impair the entire pipeline rather than a single asset. More broadly, biotechnology competition, reimbursement pressure, and the need for specialized manufacturing and clinical execution create additional uncertainty, while geopolitical and market volatility can make financing more difficult.

- **Going concern and financing shortfall** [critical] — The company disclosed that current cash may not fund operations for at least twelve months and that it will need substantial additional capital.
- **Clinical development failure or delay** [high] — Pipeline value depends on successful Phase 1/2 execution and eventual regulatory approval.
- **Dependence on CAB technology platform** [high] — The company’s future success is tied heavily to the performance of its patented CAB approach.
- **Commercialization and partner execution risk** [medium] — BioAtla currently lacks a marketing and sales organization and may need third parties to commercialize any approved product.
- **Competitive and regulatory risk** [medium] — Larger competitors may reach approval sooner, and regulators may impose safety, labeling, or REMS constraints.

- No approved products, so the business depends on clinical success
- Substantial doubt about going concern increases financing risk
- Pipeline concentration in the CAB platform creates platform-level risk
- Clinical failures or delays can destroy asset value
- Competition from better-funded biotech peers can limit partnering and approval odds
- Safety, labeling, or REMS requirements could reduce commercial attractiveness
- Need for third-party manufacturing and trial execution adds operational risk
- Market volatility can restrict access to equity or debt capital

## Accounting

BioAtla’s accounting profile is dominated by revenue recognition from collaborations rather than product sales, so the timing of milestone and license revenue is a key judgment area. The company recognized $11.0 million of collaboration revenue in 2024 from the Context license but none in the 2025 periods shown, highlighting how volatile reported revenue can be when it depends on contract milestones and partner activity. Research and development expense is another major analytical focus because costs are allocated across individual CAB programs and include external CRO, CMO, laboratory, and personnel spending that can shift materially quarter to quarter. Investors should also watch cash-flow presentation, stock-based compensation, lease accounting, and going-concern disclosures because these affect reported losses, liquidity assessment, and comparability across periods.

- **Collaboration and license revenue recognition** — Can materially change quarterly revenue and operating loss
- **R&D accruals and program cost allocation** — Affects pipeline-level cost visibility and comparability
- **Stock-based compensation** — Inflates reported operating losses without immediate cash outflow
- **Going concern assessment** — Critical for interpreting solvency and dilution risk

- Collaboration and license revenue depends on milestone timing and contract terms
- No product revenue yet, so reported revenue can be lumpy and non-recurring
- R&D expense allocation by program affects how pipeline economics are viewed
- Clinical trial and manufacturing accruals require judgment and can move quarterly results
- Stock-based compensation is a meaningful non-cash expense in a pre-commercial biotech
- Lease and depreciation charges affect operating loss but not cash burn directly
- Going concern disclosure is important for interpreting liquidity and valuation

---

*Last updated: 2026-08-11T04:46:23.747861+00:00*